Key result
VKAs still dominate PE treatment in Serbia despite significant institutional variation.
Observational (n=863)
Yes
In a Serbian nationwide registry, VKAs remain predominantly used for pulmonary embolism, though NOAC use is increasing and varies significantly based on institutional preference, renal function, and bleeding risk.
Answers are grounded in this paper and cite their sources.
Institutional variation in PE anticoagulant choice persists in Serbia; leaves open real-world effectiveness and safety comparisons.
Introduction. Pulmonary embolism (PE) is one of the major cause of hospitalization and morbidity. All studies that compared efficacy and safety of novel oral anticoagulants (NOACs) to vitamin K antagonists (VKAs) in the treatment of PE, have showed that all NOACs were equally effective as VKAs, but superior in safety. Materials and Methods. This retrospective study included 1095 of patients from the Serbian Academic Pulmonary Embolism Registry (SAPERE) with a confirmed diagnosis of PTE treated in Military Medical Academy Belgrade, Institute for Pulmonary Diseases and Institute for Cardiovascular Diseases Vojvodina, Clinical Center Niš, Kragujevac, Banja Luka, General Hospital Pančevo, Clinical Hospital Center Zemun and Zvezdara. Results. Of the 863 total patients, NOACs were therapeutic choice in 452 (52.4%) of patients.The most preferred NOAC in Military Medical Academy was Rivaroxaban, which was therapeutic choice in 117 (33.8%) of patients in this institution. On the other hand, VKAs were administered in 103 (88.0%) of patients treated in University Clinical Center Kragujevac. The use of different type of OACs was greatly influenced by the year of PE diagnosis. From 2018, VKAs are drastically less used for the treatment of PE, while the use of Rivaroxaban and Apixaban is slowly rising. The use of OACs was also influenced by the initial treatment with/without thrombolysis, value of Creatinin Clearence (CrCl) on admission, history of previous major or non-major bleeding, presence of active malignancy and HAS-BLAD score value. Conclusion. In Serbia, VKAs are still predominantly used in the treatment of PE, however, decision of the type of OAC (VKAs or NOACs) used in the treatment of this patient population greatly varies between health institutions from Serbia.
No takes yet. Share an insight, caveat, or question.
Nikolić et al. (2020) conducted an observational in Pulmonary Thromboembolism (n=863). Non-Vitamin K Antagonists (NOACs) vs. Vitamin K Antagonists (VKAs) was evaluated on Overall hospital death and PE related death rates. In Serbia, Vitamin K Antagonists are still predominantly used in the treatment of Pulmonary Embolism, though the choice of anticoagulant varies significantly between institutions.
Synapse has enriched 10 related papers. Consider them for comparative context: